The Effect of Switching Therapy to Pegaptanib in Eyes with the Persistent Cases of Exudative Age-related Macular Degeneration.

Trial Profile

The Effect of Switching Therapy to Pegaptanib in Eyes with the Persistent Cases of Exudative Age-related Macular Degeneration.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 May 2016

At a glance

  • Drugs Pegaptanib (Primary) ; Ranibizumab
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top